Science and Research

Real-world walking cadence in people with COPD

INTRODUCTION: The clinical validity of real-world walking cadence in people with COPD is unsettled. Our objective was to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence. METHODS: We assessed walking cadence (steps per minute during walking bouts longer than 10 s) from 7 days' accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during a 12-month follow-up were recorded from patient reports and medical registries. RESULTS: Participants were mostly male (80%) and had mean±sd age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV(1)) of 57±19% predicted and walked 6880±3926 steps·day(-1). Mean walking cadence was 88±9 steps·min(-1), followed a normal distribution and was highly stable within-person (intraclass correlation coefficient 0.92, 95% CI 0.90-0.93). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV(1,) 6-min walk distance, physical activity (steps·day(-1), time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (incidence rate ratio 0.94 per step·min(-1), 95% CI 0.91-0.99, p=0.009). CONCLUSIONS: Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as a future prognostic marker and clinical outcome.

  • Delgado-Ortiz, L.
  • Ranciati, S.
  • Arbillaga-Etxarri, A.
  • Balcells, E.
  • Buekers, J.
  • Demeyer, H.
  • Frei, A.
  • Gimeno-Santos, E.
  • Hopkinson, N. S.
  • de Jong, C.
  • Karlsson, N.
  • Louvaris, Z.
  • Palmerini, L.
  • Polkey, M. I.
  • Puhan, M. A.
  • Rabinovich, R. A.
  • Rodríguez Chiaradia, D. A.
  • Rodriguez-Roisin, R.
  • Toran-Montserrat, P.
  • Vogiatzis, I.
  • Watz, H.
  • Troosters, T.
  • Garcia-Aymerich, J.
Publication details
DOI: 10.1183/23120541.00673-2023
Journal: ERJ Open Res
Number: 2
Work Type: Original
Location: Assoziierter Partner
Disease Area: COPD
Partner / Member: PRI
Access-Number: 38444656

DZL Engagements

chevron-down